Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Paxalisib (GDC-0084) in Recurrent or Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT04906096 is registered in ClinicalTrials.gov with Lakshmi Nayak, MD as lead sponsor.

NCT NCT04906096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04906096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Paxalisib (GDC-0084) in Recurrent or Refractory Primary Central Nervous System Lymphoma (PCNSL)
Lead sponsor
Lakshmi Nayak, MD
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2021
Completion date
December 1, 2027
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma of extranodal site, primary central nervous system lymphoma